

## BIBLIOGRAFIA

1. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. *Gastroenterology* 1999; 116(6): 1453-6.
2. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96(4): 261-8.
3. Vasen HF, Mösllein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). *J Med Genet* 2007; 44(6): 353-62.
4. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. *JAMA* 2006; 296(12): 1507-17.
5. Ramsoekh D, Van Leerdaam ME, Wagner A, et al. Review article: Detection and management of hereditary non-polyposis colorectal cancer (Lynch syndrome). *Aliment Pharmacol Ther* 2007; 26 Suppl 2: 101-11.
6. Hendriks YM, de Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. *CA Cancer J Clin* 2006; 56(4): 213-25.
7. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumors in patients with Lynch syndrome. *Lancet Oncol* 2009; 10: 400-8.
8. Yu VP, Novelli M, Payne SJ, et al. Unusual presentation of Lynch Syndrome. *Hered Cancer Clin Pract* 2009; 7(1): 12.
9. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. *Gastroenterology* 2004; 127(1): 17-25.
10. Zhao YS, Hu FL, Wang F, et al. Meta-analysis of MSH6 gene mutation frequency in colorectal and endometrial cancers. *J Toxicol Environ Health A* 2009; 72(11): 690-7.
11. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Engl J Med* 2003; 348(10): 919-32.
12. Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. *BMJ* 2005; 331(7524): 1047.
13. Stoffel EM, Turgeon DK, Stockwell DH, et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). *Cancer Prev Res (Phila Pa)* 2008; 1(6): 470-5.
14. McIlhatton MA, Tyler J, Burkholder S, et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. *Cancer Res* 2007; 67(22): 10966-75.
15. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. *N Engl J Med* 2008; 359(24): 2567-78.
16. Lynch HT, Boland CR, Gong G, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. *Eur J Hum Genet* 2006; 14(4): 390-402.
17. de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. *Gut* 2003; 52(12): 1752-5.
18. Grindeland EM, Blanco I, Stormorken A, et al. High risk of endometrial cancer in colorectal cancer kindred is pathognomonic for MMR-mutation carriers. *Fam Cancer* 2009; 8(2): 145-51.
19. Vasen HF, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. *J Clin Oncol* 2001; 19(20): 4074-80.
20. Plaschke J, Engel C, Krüger S, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. *J Clin Oncol* 2004; 22: 4486-94.
21. Broaddus RR, Lynch HT, Chen LM. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. *Cancer* 2006; 106(1): 87-94.
22. Boks DE, Trujillo AP, Voogd AC, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2002; 102(2): 198-200.
23. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. *J Clin Oncol* 2008; 26(36): 5965-71.
24. Manchanda R, Menon U, Michaelson-Cohen, et al. Hereditary nonpolyposis colorectal cancer or Lynch syndrome: the gynecological perspective. *Curr Opin Obstet Gynecol* 2009; 21(1): 31-8.
25. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008; 123(2): 444-9.
26. Pal T, Permuth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. *Clin Cancer Res* 2008; 14(21): 6847-54.
27. Mann A, Hogdall E, Ramus SJ, et al. Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. *Eur J Cancer* 2008; 44(15): 2259-65.
28. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. *CA Cancer J Clin* 2009; 59(1): 27-41.
29. Rijken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol* 2003; 91(1): 74-80.
30. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer* 2002; 94(6): 1708-12.
31. Epstein E, Valentin L. Managing women with post-menopausal bleeding. *Best Pract Res Clin Obstet Gynaecol* 2004; 18(1): 125-43.
32. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol* 2009; 10(4): 327-40.
33. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. *Am J Epidemiol* 2007; 166(8): 894-901.
34. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med* 2006; 354(3): 261-9.
35. Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. *Obstet Gynecol* 2007; 110(1): 18-25.
36. Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. *Clin Cancer Res* 2000; 6(8): 2994-8.
37. Gylling A, Abdel-Rahman WM, Juhola M, et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. *Gut* 2007; 56(7): 926-33.